Steven G. Gray
St. James’s Hospital, Ireland
- Orcid: 0000-0002-5850-6392
- Publications: N/A
- Citations: N/A
- Keywords: NSCLC, Mesothelioma, non-coding RNA, Chromatin, Epigenetics, Biomarker, cfRNA, cfDNA
Short Bio
- Dr Steven Gray Steven Gray graduated from Trinity College Dublin in 1992. He joined the laboratory of Tomas J. Ekstrom at the Karolinska Institute (Sweden) in 1996 and received his PhD in 2000 (Thesis Title: The IGF-axis in liver disease: Modulation of expression by histone deacetylase inhibitors). He moved to the Van Andel Research Institute in Michigan, USA where he continued his studies on the therapeutic potential of histone deacetylase inhibitors in the treatment of cancer. He also spent some time as a visiting fellow at Harvard Medical School, Boston working on epigenetic therapies for neurodegenerative disease. Returning to Europe, Dr Gray spent some time at the German Cancer Research Centre (DKFZ - Heidelberg), and subsequently moved to Copenhagen to work for Novo Nordisk as part of the research team of Prof Pierre De Meyts at the Hagedorn Research Institute working on epigenetic mechanisms underpinning diabetes pathogenesis. Dr Gray is currently a senior clinical scientist at St James's Hospital at the Thoracic Oncology Research Group at St. James's Hospital. He holds adjunct positions at both Trinity College Dublin (senior clinical lecturer), and at Technical University of Dublin (adjunct senior lecturer). Dr Gray’s research interests onclude: 1. cfRNA & cfDNA as candidate biomarkers in thoracic malignancy. 2. Epigenetic mechanisms underpinning drug resistance in lung cancer. 3. Targeting Epigenetic Readers, Writers and Erasers for the treatment of Mesothelioma and Thoracic malignancy. 4. non-coding RNA repertoires in Mesothelioma and Thoracic malignancy. 5. Targeting fibrosis to improve drug delivery and response in NSCLC and mesothelioma.
